Pathologic features of chronic hepatitis: A review and update

American Journal of Clinical Pathology

Volumn 113, Issue 1, 2000, Pages 40-55

  Ishak, Kamal G ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Autoimmune hepatitis; Chronic hepatitis B; Chronic hepatitis C; Nomenclature; Pathology

Indexed keywords

APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; CYTOPATHOLOGY; DELTA AGENT HEPATITIS; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER NECROSIS; NOMENCLATURE; PRIORITY JOURNAL;

EID: 0034049101     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/42d6-w7pl-fx0a-lbxf     Document Type: Article

References (138)

1. Lau JYN, Xie X, Lai MMC, et al. Apoptosis and viral hepatitis. Semin Liver Dis. 1998;18:169-176.
2. Hassan G, Moreno S, Massimi M, et al. Interleukin-1 producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis. J Hepatol. 1997; 27:6-17.
3. 1 in chronic hepatitis C. J Viral Hepatol. 1997;4:29-35.
4. Zylberberg H, Rimaniol A-C, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol. 1999;30:185-191.
5. Marinos G, Naumov NV, Rossol S, et al. Tumor necrosis factor in patients with chronic hepatitis B virus infection. Gastroenterology. 1995;108:1453-1463.
6. Fang JWS, Shen WW, Meager A, et al. Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol. 1996;91:748-753.
7. Mosnier J-F, Degott C, Marcellin P, et al. The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology. 1993;17:366-371.
8. Allaire GS, Goodman ZG, Ishak KG, et al. Talc in liver tissue of intravenous drug abusers with chronic hepatitis: a comparative study. Am J Clin Pathol. 1989;92:583-588.
9. Sherman KE, Lewey SM, Goodman ZD. Talc in the liver of patients with chronic hepatitis C infection. Am J Gastroenterol. 1995;90:2164-2166.
10. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol. 1994;7:690-713.
11. Kaji K, Nakanuma Y, Sasaki M, et al. Hepatic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Mod Pathol. 1994;7:937-945.
12. Vyberg M. The hepatitis-associated bile duct lesion. Liver. 1993;13:289-301.
13. Kaji K, Nakanuma Y, Harada K, et al. Dendritic cells in portal tracts in chronic hepatitis C and primary biliary cirrhosis: an immunohistochemical study. Hepatol Res. 1997;8:1-12.
14. Banner BF, Allan C, Smith L, et al. Effect of interferon therapy on bile duct inflammation in hepatitis C. Virchows Arch. 1996;428:253-259.
15. Sheen I-S, Liaw Y-F, Lin D-Y, et al. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol. 1996;24:525-531.
16. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347:92-93.
17. Kao J-H, Chen P-J, Lai M-Y, et al. Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis. J Infect Dis. 1994;170:1128-1133.
18. Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol. 1998;93:1563-1565.
19. Hegarty JE, Aria KTN, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685-689.
20. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology. 1963;44:239-242.
21. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 1999;116:378-386.
22. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis: quantitative assessment by a morphometric method. J Hepatol. 1998;29:20-28.
23. Dufour J-F, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127:981-985.
24. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983-994.
25. Bianchi L, Gudat F. Sanded nuclei in hepatitis B. Lab Invest. 1976;35:1-5.
26. Moreno A, Ramon Y, Cajal S, et al. Sanded nuclei in delta patients. Liver. 1989;9:367-571.
27. Chu C-M, Liaw Y-F. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection: hepatocytes with cytoplasmic/membranous hepatitis B core antigen as a possible target for immunohepatocytolysis. Gastroenterology. 1987;92: 220-225.
28. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol. 1995;17:261-281.
29. Negro F, Pacchioni D, Mondardini A, et al. In situ hybridization in viral hepatitis. Liver. 1992;12(special issue):217-226.
30. Keeffe E. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201-205.
31. Pontisso R, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529-1533.
32. Zarski J-P, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28:27-33.
33. Liaw Y-F, Tsai S-L, Sheen IS, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998;93: 354-359.
34. Liaw Y-F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101-1108.
35. Colin J-F, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection in chronic hepatitis B in homosexual men. Hepatology. 1999;29: 1306-1310.
36. Bianchi L, Desmet VJ, Popper H, et al. Histologic patterns of liver disease in hemophiliacs with special reference to morphologic characteristic of non-A, non-B hepatitis. Semin Liver Dis. 1987;7:203-209.
37. Lefkowitch JH, Apfelbaum TF. Non-A, non-B hepatitis: characterization of liver biopsy pathology. J Clin Gastroenterol. 1989;11:225-232.
38. Czaja AJ, Carpenter HA, Santrach PJ, et al. Host-and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29:198-206.
39. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459-466.
40. Emile JF, Sebagh M, Féray C, et al. The presence of epithelioid granulomas in hepatitis C virus - related cirrhosis. Hum Pathol. 1993;24:1095-1097.
41. Goldin RD, Levine TS, Foster GR, et al. Granulomas and hepatitis C. Histopathology. 1996;28:265-267.
42. Veerabagu MP, Finkelstein SD, Rabinovitz M. Granulomas in a patient with chronic hepatitis C treated with interferon-alpha. Dig Dis Sci. 1997;42:1445-1448.
43. Okuno T, Arai K, Matsumoto M, et al. Epithelioid granulomas in chronic hepatitis C: a transient pathological feature. J Gastroenterol Hepatol. 1995;10:532-537.
44. Sebagh M, Farges O, Emile J-F, et al. An unusual pattern of hepatitis C virus infection in a liver allograft. Histopathology. 1995;27:190-192.
45. Harada K, Minato H, Hiramatsu K, et al. Epithelioid cell granulomas in chronic hepatitis C: immunohistochemical character and histological marker of favorable response to interferon-alpha therapy. Histopathology. 1998;33:216-221.
46. Hu B, French SW. Mallory body and empty cell in hepatitis C. Hepatol Res. 1997;8:13-20.
47. Barton AL, Banner BF, Cable EE, et al. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 1995;103:419-424.
48. Ikura Y, Morimoto H, Johmura H, et al. Relationship between iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol. 1996;91:1367-1373.
49. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology. 1999;116:127-134.
50. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-768.
51. Gonzalez-Peralta RP, Lau JYN. Pathogenesis of hepatocellular damage in chronic hepatitis C infection. Semin Gastrointest Dis. 1995;6:28-34.
52. Nelson DR, Lau JYN. Pathogenesis of hepatocellular damage in chronic hepatitis virus infection. Clin Liver Dis. 1997;1:515-528.
53. Dries V, von Both I, Müller M, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology. 1999;29:223-229.
54. Brody RI, Eng S, Melamed J, et al. Immunohistochemical detection of hepatitis C antigen by monoclonal antibody TORDJI-22 compared with PCR viral detection. Am J Clin Pathol. 1998;110:32-37.
55. Vartanian RR, Dupuis B, Rock N, et al. Nonspecificity of the novel paraffin-reactive hepatitis C virus, clone TORDJI-22. Lab Invest. 1996;74:138A.
56. Doughty AL, Painter DM, McCaughan GW. Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. Liver Transpl Surg. 1999;5:40-45.
57. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-290.
58. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C [letter]. N Engl J Med. 1998;338:1771.
59. Spengler U, Rockstroh JK. Hepatitis C in the patient with human immunodeficiency virus infection. J Hepatol. 1998;29:1023-1030.
60. Gordon SC, Elloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs intravenous drug use. Hepatology. 1993; 18:1338-1343.
61. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125:634-639.
62. Zeuzem S, Franke A, Lee J-H, et al. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology. 1996;24: 1003-1009.
63. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med. 1997;336:747-754.
64. Batts KP. Hepatitis G: a virus in search of a disease. Am J Clin Pathol. 1997;108:616-618.
65. Mphahlele MJ, Lau GKK. HGV: the identification, biology and prevalence of an orphan virus. Liver. 1998;18:143-155.
66. Yashina TL, Favorov MO, Khudyakov YE, et al. Detection of hepatitis G virus (HGV) RNA: clinical characteristics of acute HGV infection. Infect Dis. 1997;175:1302-1307.
67. Alter MJ, Gallagher M, Morris TT, et al. Acute non - A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med. 1997;336:741-746.
68. Bralet M-P, Roudot-Thoraval F, Pawlotsky J-M, et al. Histopathologic impact of GB virus C infection on chronic hepatitis C. Gastroenterology. 1997;112:188-192.
69. Goldstein NS, Underhill J, Gordon SC, et al. Comparative histologic features of liver biopsy specimens with hepatitis G and C viruses with chronic hepatitis C virus alone: an age-, sex-, disease duration-, and transmission-matched controlled study of chronic hepatitis. Am J Clin Pathol. 1997; 108:625-632.
70. Inoue K, Yoshiba M, Sekiyama, et al. Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G. J Hepatol. 1999;30:801-806.
71. Simmonds P, Davidson F, Lycett C, et al. Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet. 1998;352:191-195.
72. Charlton M, Poterucha J, Zein N, et al. TT-virus in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998; 28:839-842.
73. Ikeda H, Takasu M, Inoue K, et al. Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease of unknown etiology and in those positive for hepatitis C virus RNA. J Hepatol. 1999;30: 205-212.
74. Naoumov NV, Petrova EP, Thomas MG, et al. Presence of a newly described DNA virus (TTV) in patients with liver disease. Lancet. 1998;352:195-197.
75. Thursz MR, Thomas HC. Host factors in chronic viral hepatitis. Semin Liver Dis. 1997;17:345-350.
76. Rosman AS, Waraich A, Galvin K, et al. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol. 1996;91:198-205.
77. Schiff ER. Hepatitis C and alcohol. Hepatology. 1997;26(suppl 1):39S-42S.
78. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;20:805-809.
79. Miller M, Crippin JS, Klintmalm G. End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Am J Gastroenterol. 1996;91:1427-1429.
80. Navas S, Bosch O, Castillo I, et al. Porphyria cutanea tarda and hepatitis C and B virus infections: a retrospective study. Hepatology. 1995;21:279-284.
81. Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology. 1992;16:1322-1362.
82. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone M, et al. Porphyria cutanea tarda, hepatitis C and HFE gene mutations in North America. Hepatology. 1998;27:1661-1699.
83. Sheikh MY, Eber BB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci. 1998;43:529-533.
84. Lenzi M, Ballardini G, Fusconi M, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 1990;335:258-259.
85. Garson JA, Lenzi M, Ring C, et al. Hepatitis C viraemia in adults with type 2 autoimmune hepatitis. J Med Virol. 1991;34:223-226.
86. Todros L, Touscoz G, D'Urso N, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). J Hepatol. 1991;13:128-131.
87. Giostra F, Manzin A, Lenzi M, et al. Low hepatitis C viremia in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol. 1996;25:433-438.
88. Reddy KR, Krawitt EI, Homberg J-C, et al. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat. 1995;2:175-179.
89. Abuaf N, Johenet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892-898.
90. Vento S, Cainelli F, Renzini C, et al. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet. 1997;350:1298-1299.
91. Zein NN, Persing DH, Czaja AJ. Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Mayo Clin Proc. 1999;74:454-460.
92. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21:613-619.
93. Gregorio GV, Jones H, Choudhuri K, et al. Autoantibody prevalence in chronic hepatitis B virus infection: effect of interferon alfa. Hepatology. 1996;24:520-523.
94. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005.
95. Dienes HP, Gerken G, Lohse AW, et al. In: Berg P, Lohse AW, Tiegs G, et al, eds. Autoimmune Liver Disease. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1997:80-85.
96. Lefkowitch JH, Apfelbaum TF, Weinberg L, et al. Acute liver biopsy lesions in early autoimmune ("lupoid") chronic active hepatitis. Liver. 1984;4:379-386.
97. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303-307.
98. Pratt DS, Fawaz KA, Rabson A, et al. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664-668.
99. Motoo Y, Sawabu N, Watanabe H, et al. Prolonged intrahepatic cholestasis in acute-onset, severe autoimmune hepatitis. J Gastroenterol. 1997;32:410-413.
100. Herzog D, Rasquin-Weber A-M, Debray D, et al. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol. 1997;27: 578-582.
101. Richey J, Rogers S, Van Thiel DH, et al. Giant multinucleated hepatocytes in an adult with chronic active hepatitis. Gastroenterology. 1977;73:570-574.
102. Bernard O, Hadchouel M, Scotto J, et al. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr. 1981;99:704-711.
103. Shinozaki T, Saito K, Shiraki K. HBsAg-positive giant-cell hepatitis with cirrhosis in a 10-month-old infant. Arch Dis Child. 1981;56:64-66.
104. Thaler H. Post-infantile giant cell hepatitis. Liver. 1982;2:393-403.
105. Thijs JC, Bosna KA, Henzen-Logmans SC, et al. Post-infantile giant cell hepatitis in a patient with multiple autoimmune features. Am J Gastroenterol. 1985;80:294-297.
106. Britchard B, Sokal E, Buts JP, et al. Coombs-positive giant cell hepatitis of infancy: effect of steroids and azathioprine therapy. Eur J Pediatr. 1991;150:314-317.
107. Phillips MJ, Blendis LM, Poucell S, et al. Syncytial giant cell hepatitis: sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Eng J Med. 1991;324:455-460.
108. Fimmel CJ, Guo L, Compano RW, et al. A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. Am J Gastroenterol. 1998;93:1931-1937.
109. Devaney K, Goodman ZD, Ishak KG. Post-infantile giant-cell transformation in hepatitis. Hepatology. 1992;16:327-333.
110. Lau JYN, Koukoulis G, Mieli-Vergani G, et al. Syncytial giant-cell hepatitis: a specific disease entit? J Hepatol. 1992;15:216-219.
111. Sanna G, Faa G, Forresu S, et al. Syncytial giant cell hepatitis: a new form of chronic liver disease. Eur J Intern Med. 1993;4:155-158.
112. Weinstein U, Valderrama E, Pettei M, et al. Early steroid therapy for the treatment of giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr. 1993;17:313-316.
113. Johnson SJ, Mathew J, MacSween RNM, et al. Post-infantile giant cell hepatitis: histological and immunohistochemical study. J Clin Pathol. 1994;47:1022-1027.
114. Cairns A, McMabon RFT. Giant cell hepatitis associated with systemic lupus erythematosus. J Clin Pathol. 1996;49:183-184.
115. Pappo O, Yunis E, Jordan JA, et al. Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol. 1994;18:804-813.
116. Durand F, Degott C, Sauvanet A, et al. Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J Hepatol. 1997;26:722-726.
117. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990;65:23-30.
118. Brown J, Dourakis S, Karayainnis P, et al. Seroprevalence of hepatitis C virus nucleocapsid antibodies with cryptogenic chronic liver disease. Hepatology. 1992;15:175-179.
119. Sanchez-Tapias JM, Barrera JM, Costa J, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med. 1990;112:921-924.
120. Greeve M, Ferrell L, Kim M, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology. 1993;17:593-598.
121. Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755-1761.
122. Caldwell SH, Oelsner DH, Lezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.
123. Goldstein NS, Kodali V-P, Gordon SC. Histologic spectrum of cryptogenic chronic liver disease and comparison with chronic autoimmune and chronic type C hepatitis. Am J Clin Pathol. 1995;104:567-573.
124. Strader DB, Seeff LB. Drug-induced chronic liver disease. Clin Liver Dis. 1998;2:501-522.
125. Zimmerman HJ. Drug-induced liver injury: clinical. In: Bloomer JR, Goodman ZD, Ishak KG, eds. Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium. Washington, DC: Armed Forces Institute of Pathology; 1998:252-268.
126. Sternlieh I, Scheinberg IH. Chronic hepatitis as a first manifestation of Wilson's disease. Ann Intern Med. 1972;76:59-64.
127. Scott J, Gollan JL, Samourian S, et al. Wilson's disease presenting as chronic active hepatitis. Gastroenterology. 1978;74:645-651.
128. 1-antitrypsin deficiency in adults with chronic hepatitis and cryptogenic cirrhosis. N Engl J Med. 1981;504:557-560.
129. Propst T, Propst A, Dietze O, et al. High prevalence of viral infection in adults with homozygous and heterozygous alpha-antitrypsin deficiency and chronic liver disease. Ann Intern Med. 1992;117:641-645.
130. 1-antitrypsin deficiency and liver disease. Dig Dis. 1994;12:139-149.
131. 1-antitrypsin deficiency. Acta Paediatr Suppl. 1994;395:24-26.
132. 1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. 1998;93:1541-1545.
133. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
134. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-1520.
135. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
136. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
137. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
138. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-293.